AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Curanex Pharmaceuticals Inc Common Stock

$4.55 -$2.82 (-38.26%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$4.31
Day Range
$4.33$4.69
Year Range
$3.58$183.6
Market Cap
6.45M
AVG Volume
11.3K
Trailing/Forward PE
-0.62/-
PEG ratio
0.01
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
NASDAQUS
Net Income (USD) · TTM
-15M-10M-5M024 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CURX Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-10.47M
26 Q1-7.24M
25 Q4-4.23M
25 Q3-1.29M
25 Q2-435.03K
25 Q1-418.89K
24 Q4-361.51K
24 Q3-237.01K
Operating Income (USD) · TTM
-15M-10M-5M024 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CURX Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-10.55M
26 Q1-7.28M
25 Q4-4.24M
25 Q3-1.29M
25 Q2-435.77K
25 Q1-422.31K
24 Q4-365.06K
24 Q3-239.14K
EBITDA (USD) · TTM
-15M-10M-5M024 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CURX EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-10.43M
26 Q1-7.18M
25 Q4-4.16M
25 Q3-1.16M
25 Q2-329.8K
25 Q1-331.78K
24 Q4-290.39K
24 Q3-239.14K
Cash Flows (USD) · TTM
-15M-10M-5M025 Q426 Q126 Q2
CURX Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-12.08M
26 Q1-11.29M
25 Q4-10.48M
EPS (USD) · TTM
-8-6-4-2024 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CURX EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-7.38
26 Q1-5.1
25 Q4-2.98
25 Q3-0.82
25 Q2-0.15
25 Q1-0.11
24 Q4-0.01
24 Q3-0.01
Expenses (USD) · TTM
05M10M15MR&DSG&A24 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CURX Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q210.52M
26 Q17.25M
25 Q44.2M
25 Q31.21M
25 Q2361.1K
25 Q1347.64K
24 Q4290.39K
24 Q3239.14K
Shares Outstanding · TTM
-10K-7.5K-5K-2.5K025 Q426 Q126 Q2
CURX Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
26 Q2-9.79K
26 Q1-9.79K
25 Q40
Employee Count
024682025
CURX Employee Count by quarter
PeriodEmployee Count
20256
Free Cash Flow Yield
-250%-200%-150%-100%-50%med -146.13%Apr 26May 26Jun 26Jul 26Aug 26Sep 26
CURX Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-187.19%
Sep 26-168.65%
Aug 26-186.78%
Aug 26-180.83%
Aug 26-195.79%
Aug 26-204.25%
Jul 26-194.28%
Jul 26-211.85%
Jul 26-193.81%
Jul 26-178.6%
Jul 26-156.19%
Jun 26-150.01%
Jun 26-142.24%
Jun 26-124.07%
Jun 26-131.45%
May 26-119.78%
May 26-120.14%
May 26-132.54%
May 26-114.53%
May 26-99.98%
Apr 26-84.65%
Apr 26-82.03%
Apr 26-79.73%
Apr 26-75.5%
Price to Book
0200400600800med 0.97Oct 25Dec 25Jan 26Mar 26May 26Jul 26Sep 26
CURX Price to Book by quarter
PeriodPrice to Book
Sep 261.35
Sep 261.5
Aug 261.35
Aug 261.4
Aug 261.29
Aug 260.68
Jul 260.72
Jul 260.66
Jul 260.72
Jul 260.78
Jul 260.89
Jun 260.93
Jun 260.98
Jun 261.13
Jun 261.06
May 261.17
May 261.16
May 261.05
May 260.82
May 260.93
Apr 261.1
Apr 261.14
Apr 261.17
Apr 261.24
Mar 260.95
Mar 260.91
Mar 260.76
Mar 260.77
Feb 260.89
Feb 260.61
Feb 260.57
Feb 260.55
Jan 260.64
Jan 260.71
Jan 260.71
Jan 260.74
Jan 260.73
Dec 250.72
Dec 250.74
Dec 250.9
Dec 250.86
Nov 250.97
Nov 250.8
Nov 2546.02
Nov 2556.33
Oct 2561.55
Oct 2560.01
Oct 2555.38
Oct 2563.46
Oct 2570.87
Sep 2571.78
Sep 25108.12
Sep 25781.35
Sep 25548.51
Aug 25424.85
Curanex Pharmaceuticals Inc Common Stock
CURX
Stockpicker

Video analysis: CURX

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.